A rat model for retinitis pigmentosa with rapid retinal degeneration enables drug evaluation in vivo

• Main Authors: Chisato Inoue, Tamaki Takeuchi, Akira Shiota, Mineo Kondo, Yuji Nshizawa
• Format: Article
• Language: English
• Published: BMC 2021-06-01
• Series: Biological Procedures Online
• Subjects: Rapamycin; Retina; Photoreceptor; Rat model; Retinitis pigmentosa; Retinal degeneration
• Online Access: https://doi.org/10.1186/s12575-021-00150-y

Abstract Background Although retinitis pigmentosa (RP) is most frequently studied in mouse models, rats, rabbits, and pigs are also used as animal models of RP. However, no studies have reported postnatal photoreceptor cell loss before complete development in these models. Here, we generated a transgenic rat strain, named the P347L rat, in which proline at position 347 in the rhodopsin protein was replaced with leucine. Results A pathological analysis of photoreceptor cells in the P347L rat model was performed, and drugs with potential use as therapeutic agents against RP were investigated. The data clearly showed rapid degeneration and elimination of the outer nuclear layer even before the photoreceptor cells were fully established in P347L rats. To test the usefulness of the P347L rat in the search for new therapeutic agents against RP, the effects of rapamycin on RP were investigated in this rat strain. The findings suggest that rapamycin promotes autophagy and autophagosomal uptake of the rhodopsin that has accumulated abnormally in the cytoplasm, thereby alleviating stress and delaying photoreceptor cell death. Conclusions In this RP model, the time to onset of retinal degeneration was less than that of previously reported RP models with other rhodopsin mutations, enabling quicker in vivo evaluation of drug efficacy. Administration of rapamycin delayed the photoreceptor cell degeneration by approximately 1 day.